

Charity number: 1123760
Company number: 6078396
(England and Wales)

British Society for Histocompatibility and Immunogenetics
Report of the Trustees and Unaudited Financial Statements
For the year ended 31 December 2019



British Society for Histocompatibility and Immunogenetics
Contents Page
For the year ended 31 December 2019

Report of the Trustees	1 to 3
Independent Examiner's Report to the Trustees	4
Statement of Financial Activities	5
Statement of Financial Position	6
Notes to the Financial Statements	7 to 12

British Society for Histocompatibility and Immunogenetics
Report of the Trustees
For the year ended 31 December 2019

The Trustees, who are also directors for the purposes of company law, have pleasure in presenting their report and the financial statements for the charitable company for the year ended 31 December 2019. The Trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2015).

OBJECTIVES AND ACTIVITIES

The objects of the Society, as stated in its Memorandum of Association, are;

To promote and protect health for the public benefit in particular by:

(a) developing and maintaining good practice in Histocompatibility and Immunogenetics by ensuring the highest professional standards of competence;

(b) encouraging the advancement of scientific research and knowledge and of its application in all aspects of Histocompatibility and Immunogenetics and disseminating the useful results thereof.

The main activities of the society that contribute to the achievement of the objectives are;

Annual Conference

The BSHI Annual Conference was held at College Court Conference Centre, Leicester. The meeting provided an educational programme of lectures and seminars. Plenary lectures were provided by world experts in the field of Histocompatibility and Immunogenetics. Sessions were run allowing BSHI Members to present short papers and posters of their current research to a worldwide audience of experts.

Two awards sessions were held. The first for best abstract submitted and a session dedicated to presentations from young scientists within the society.

Objectives and aims

The trustees have considered the Charity Commission's guidance on public benefit, including the guidance 'public benefit: running a charity (PB2)'.

ACHIEVEMENTS AND PERFORMANCE

Diploma and other training courses

A successful series of one and two day training courses were held to support Trainee Clinical Scientists, Biomedical Scientists and those undertaking higher qualifications. Graduation diplomats received their awards at the Annual Conference.

BSHI ran a higher training meeting for members considering taking the FRC Path examinations.

BSHI also administers a CPD scheme for the membership.

British Society for Histocompatibility and Immunogenetics
Report of the Trustees Continued
For the year ended 31 December 2019

ACHIEVEMENTS AND PERFORMANCE continued

Special Interest Groups

The three special interest groups were all busy this year providing educational workshops and forums for discussion between the different laboratories. The 3 active SIGs are the Antibody SIG, the Next Generation Sequencing SIG and the Haematopoietic Stem Cell SIG.

Bursaries and Grants

BSHI supplied bursaries to its members to attend scientific and educational meetings. These included the European Federation of Immunogenetics and British Society for Histocompatibility and Immunogenetics meetings.

The society also awarded the Julia Bodmer Travel Award, which allows a junior member of the society the opportunity to visit another laboratory to bring back some research ideas or new technology to their own laboratory. The recipient of the award presents their findings at the BSHI annual conference.

Representation to other professional bodies

The BSHI has nominated representatives to a number of other professional organisations and these representatives link to the BSHI Committee through the Professional Advisory Group. Elected members of BPAG are responsible for co-ordinating BSHI input to official working groups and documents.

BSHI is represented at the Association of Clinical Scientists, Clinical Pathology Accreditation UK Ltd, the Federation of Healthcare Science, the National External Quality Assurance Advisory Panel for Immunology, and the Royal College of Pathologists and ODT advisor groups.

Establishment and maintenance of appropriate standards within H & I is addressed through the BPAG. BPAG will interact with other professional organisations e.g. European Federation for Immunogenetics, British Transplantation Society as required and set up Standards Working Groups to address specific topics.

Online Virtual Conference Facility

BSHI provides virtual conference infrastructure via Cisco Webex to the memberships, enabling remote conferencing and education to take place and at the same time reducing waste and carbon impact.

Online Scientific Journals

BSHI continues to supply access to scientific literature that members do not readily have access to.

Publications

BSHI publishes a quarterly newsletter which is sent to all of the memberships. This contains reports from meetings, CPD journal based learning exercises and updates on developments within the society.

FINANCIAL REVIEW

Reserves

The overall reserves of the charity have increased slightly to £141,652 leaving the charity in a strong position to continue to pursue its objectives for the foreseeable future.

REFERENCE AND ADMINISTRATIVE INFORMATION

Name of Charity	British Society for Histocompatibility and Immunogenetics
Charity registration number	1123760
Company registration number	6078396
Principal address	C/O Executive Business Support Ltd City Wharf Davidson Road Lichfield Staffs WS14 9DZ

British Society for Histocompatibility and Immunogenetics
Report of the Trustees Continued
For the year ended 31 December 2019

Trustees

The trustees and officers serving during the year and since the year end were as follows:

Olivia Shaw Resigned 26th June 2019
Sarah Peacock
Richard Battle
Mian Chen
Marie Hampson
Helena Lee
Carla Rosser
Andrea Harmer
Paul Dunn
Deborah Sage Appointed 26th June 2019
Natalia Diaz Burlinson
Franco Tavarozzi Appointed 26th June 2019

Independent examiner


Marie Hartwell
Vesey Accounting Services Ltd
34 High Street
Sutton Coldfield
West Midlands
B72 1UP

Bankers

Barclays Bank Plc

Witham Business Centre
59 Newland Street
Witham
Essex
CM8 2AJ

Approved by the Board of Trustees and signed on its behalf by

A handwritten signature in dark ink, appearing to read 'Mian Chen', is written over a horizontal dotted line.

Mian Chen
Trustee

12 June 2020

British Society for Histocompatibility and Immunogenetics
Independent Examiners Report to the Trustees
For the year ended 31 December 2019

I report to the trustees on my examination of the accounts of the charitable company for the year ended 31 December 2019.

Responsibilities and basis of report

As the charity Trustees, who are also directors for the purposes of company law, are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiners qualified statement

I confirm that no other matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I confirm that there are no other matters to which your attention should be drawn to enable a proper understanding of the accounts to be reached.



Marie Hartwell

12 June 2020

VESEY Accounting Services Ltd
34 High Street
Sutton Coldfield
West Midlands
B72 1UP

British Society for Histocompatibility and Immunogenetics
Statement of Financial Activities (including Income and Expenditure Account)
For the year ended 31 December 2019

	Notes	Unrestricted funds £	2018 £
Income and endowments from:			
Charitable activities	2	69,789	86,935
Investments	3	869	677
Total		70,658	87,612
Expenditure on:			
Charitable activities	4/5	(68,829)	(97,589)
Total		(68,829)	(97,589)
Net income/expenditure		1,829	(9,977)
Reconciliation of funds			
Total funds brought forward		139,823	149,800
Total funds carried forward		141,652	139,823

British Society for Histocompatibility and Immunogenetics
Statement of Financial Position
As at 31 December 2019


	Notes	2019 £	2018 £
Fixed assets			
Intangible assets	10	2,223	4,445
Tangible assets	11	91	121
		2,314	4,566
Current assets			
Debtors	12	27,742	30,512
Cash at bank and in hand		114,716	108,537
		142,458	139,049
Creditors: amounts falling due within one year	13	(3,120)	(3,792)
Net current assets		139,338	135,257
Total assets less current liabilities		141,652	139,823
Net assets		141,652	139,823
The funds of the charity			
Unrestricted income funds	14	141,652	139,823
Total funds		141,652	139,823

For the year ended 31 December 2019 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476,

The trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statement were approved and authorised for issue by the Board and signed on its behalf by:



Mian Chen

12 June 2020

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements
For the year ended 31 December 2019

1. Accounting Policies

Basis of accounting

The financial statements have been prepared under the historical cost convention, except for investments which are included at market value and the revaluation of certain fixed assets and in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015)', Financial Reporting Standard 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), and the Companies Act 2006.

British Society for Histocompatibility and Immunogenetics meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

Going concern

The trustees are confident that BSHI will be able to continue and peruse its objectives for the foreseeable future.

Incoming resources

All incoming resources are included in the statement of financial activities when the Charity is entitled to the income and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income:

Income from investments is included in the year in which it is receivable.

Resources expended

Liabilities are recognised as resources expended when there is a legal or constructive obligation committing the Charity to the expenditure:

Intangible assets

Intangible fixed assets are measured at cost less accumulative amortisation and any accumulative impairment losses.

Tangible fixed assets

Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:

Land and buildings	4 Straight line
Plant and machinery	25 Reducing balance
Computer equipment	25 Reducing balance
Motor vehicles	25 Reducing balance
Fixtures and fittings	25 Reducing balance

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2019

2. Income from charitable activities

	2019 £	2018 £
Unrestricted funds		
<i>Charitable activities</i>		
Advertising	15,825	15,920
Subscriptions	32,620	24,075
Conference	1,205	4,097
International Journal of Immunogenetics	-	18,738
Qualifications	19,218	23,805
	68,868	86,635
 Other member activities	 920	 300
	69,788	86,935

3. Investment income

	2019 £	2018 £
Unrestricted funds		
Bank interest receivable	869	677
	869	677

4. Costs of charitable activities by fund type

	2019 £	2018 £
Unrestricted funds		
Charitable activities	35,977	50,486
Support costs	32,852	47,103
	68,829	97,589

5. Costs of charitable activities by activity type

	Activities undertaken directly £	Support costs £	2019 £	2018 £
Support costs				
Charitable activities	35,977	32,852	68,829	97,589

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2019

6. Analysis of support costs

	2019	2018
	£	£
Charitable activities		
Management	9,213	5,254
Finance	1,466	868
Computer costs	3,613	2,245
Depreciation & amortisation	2,253	2,263
EBS Admin charges	11,433	8,999
International Journal of Immunogenetics	-	22,642
Print, post & stationery	116	218
Subscriptions	794	580
Telephone	1,311	494
Governance costs	2,653	3,540
	32,852	47,103

7. Net income/(expenditure) for the year

This is stated after charging/(crediting):

	2019	2018
	£	£
Depreciation of owned fixed assets	30	40
Amortisation of intangible fixed assets	2,223	2,223
Accountancy fees	1,200	1,200

9. Comparative for the Statement of Financial Activities

The comparative year values on the Statement of Financial Activities are for unrestricted funds.

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2019

10. Intangible fixed assets

	Intangible asset 1
	£
Cost or valuation	
At 01 January 2019	6,668
At 31 December 2019	<u>6,668</u>
Amortisation	
At 01 January 2019	2,223
Charge for year	2,222
At 31 December 2019	<u>4,445</u>
Net book values	
At 31 December 2019	<u><u>2,223</u></u>
At 31 December 2018	<u><u>4,445</u></u>

11. Tangible fixed assets

	Computer equipment
	£
Cost or valuation	
At 01 January 2019	380
At 31 December 2019	<u>380</u>
Depreciation	
At 01 January 2019	259
Charge for year	30
At 31 December 2019	<u>289</u>
Net book values	
At 31 December 2019	<u><u>91</u></u>
At 31 December 2018	<u><u>121</u></u>

12. Debtors

	2019	2018
	£	£
Amounts due within one year:		
Trade debtors	10,735	6,356
Prepayments and accrued income	17,007	24,156
	<u><u>27,742</u></u>	<u><u>30,512</u></u>

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2019

13. Creditors: amounts falling due within one year

	2019	2018
	£	£
Trade creditors	3,120	3,792
	<u>3,120</u>	<u>3,792</u>

14. Movement in funds

Unrestricted Funds

	Balance at 01/01/2019	Incoming resources	Outgoing resources	Balance at 31/12/2019
	£	£	£	£
General	139,823	70,658	(68,829)	141,652
	<u>139,823</u>	<u>70,658</u>	<u>(68,829)</u>	<u>141,652</u>

Unrestricted Funds - Previous year

	Balance at 01/01/2018	Incoming resources	Outgoing resources	Balance at 31/12/2018
	£	£	£	£
General	149,800	87,612	(97,589)	139,823
	<u>149,800</u>	<u>87,612</u>	<u>(97,589)</u>	<u>139,823</u>

Purpose of unrestricted Funds

General

Unrestricted funds are funds that can only be used in accordance with the charitable objects and at the discretion of the trustees.

15. Analysis of net assets between funds

	Intangible fixed assets	Tangible fixed assets	Net current assets / (liabilities)	Net Assets
	£	£	£	£
Unrestricted funds				
General	2,223	91	139,338	141,652
	<u>2,223</u>	<u>91</u>	<u>139,338</u>	<u>141,652</u>

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2019

Previous year

	Intangible fixed assets	Tangible fixed assets	Net current assets / (liabilities)	Net Assets
	£	£	£	£
Unrestricted funds				
General	4,445	121	135,257	139,823
	4,445	121	135,257	139,823

16. Company limited by guarantee

British Society for Histocompatibility and Immunogenetics is a company limited by guarantee and accordingly does not have a share capital.